Research and Markets: Daclizumab (Multiple Sclerosis) - Forecast and Market ... Wall Street Journal (press release) PharmaPoint Drug Evaluation report, Daclizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and ... |
